» Articles » PMID: 7333326

Saliva and Plasma Clearance of Antipyrine As Reflectors of Liver Function

Overview
Date 1981 Jan 1
PMID 7333326
Authors
Affiliations
Soon will be listed here.
Abstract

Antipyrine kinetics, after oral administration to patients with changes in liver function were determined from data obtained by measuring drug concentration in saliva and plasma. Antipyrine kinetics calculated from saliva concentrations did not diverge from values obtained from plasma antipyrine measurements. The saliva and plasma clearance rates were reduced in parallel in subjects with liver parenchymal disease, and showed similar increases in subjects with normal liver treated with enzyme inducing drugs as compared to values in subjects with normal liver and no inducing treatment. The clearance values were related to changes in liver histology. The area under the concentration/time curve was increased in subjects with altered liver histology, and reduced in subjects with normal liver and therapy with enzyme inducing drugs. Antipyrine saliva clearance seems to be a useful method for assessing hepatic drug metabolism and liver microsomal function in vivo in subjects with varying degrees of liver function damage.

References
1.
Vesell E, PASSANANTI G, Glenwright P, Dvorchik B . Studies on the disposition of antipyrine, aminopyrine, and phenacetin using plasma, saliva, and urine. Clin Pharmacol Ther. 1975; 18(3):259-72. DOI: 10.1002/cpt1975183259. View

2.
Sotaniemi E, Pelkonen R, Puukka M . Measurement of hepatic drug-metabolizing enxyme activity in man. Comparison of three different assays. Eur J Clin Pharmacol. 1980; 17(4):267-74. DOI: 10.1007/BF00625800. View

3.
Ahlqvist J . Transverse mounting of ribbons on groups of slides for comparing different stains in adjacent sections. Stain Technol. 1970; 45(1):38-9. View

4.
Luoma P, Sotaniemi E, Ehnholm C . Low high-density lipoprotein and reduced antipyrine metabolism in members of a family with polycystic liver disease. Scand J Gastroenterol. 1980; 15(7):869-73. DOI: 10.3109/00365528009181544. View

5.
Brodie B, Axelrod J . The fate of antipyrine in man. J Pharmacol Exp Ther. 1950; 98(1):97-104. View